Doreen Anders
YOU?
Author Swipe
View article: Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations
Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations Open
A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO ® ) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administer…
View article: Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics Open
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI)…